Some of you might know about this game but there are people who doesnt know about the game "Re-Mission"

The Re-Mission video game for teens and young adults with cancer was released by the nonprofit HopeLab on April 3, 2006. The game is a Microsoft Windows based third-person shooter based in the serious games genre. The game was conceived by Pam Omidyar and designed based on HopeLab research, direct input from young cancer patients and oncology doctors and nurses, and game developer Realtime Associates, among others. The game was designed to engage young cancer patients through entertaining game play while impacting specific psychological and behavioral outcomes associated with successful cancer treatment.

Re-Mission is a video game that gives young people with cancer a sense of power and control over their disease. It’s a fun, effective tool that supports treatment adherence and can be used in the clinical setting or at home by patients on maintenance therapy. Re-Mission is rated “T” for teen.

Game Play

Re-Mission takes place in the bodies of 19 fictional cancer patients from diverse backgrounds. The types of cancers represented include:
  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Brain Tumor
  • Ewing’s Sarcoma
  • Hodgkin’s Lymphoma
  • Non-Hodgkin’s Lymphoma
  • Osteosarcoma

Clinical Goals

Through interactive game play, Re-Mission addresses the importance of:
  • Compliance with oral chemotherapy regimens and other prescribed medications
  • Prompt reporting of symptoms and side effects
  • Proper nutrition to increase the body’s ability to fight cancer
  • Anxiety, nausea, and pain management through breathing and muscle relaxation exercises


A randomized controlled trial showed that playing Re-Mission improves:
  • Treatment Adherence
  • Cancer Knowledge
  • Self-Efficacy


You can either order the game (for free) or download it (1.87 gb)

Get it from here

 This game is especially for children/teens suffering from cancer
Anyone can try it


  1. This comment has been removed by the author.


Please don't Spam in the comments section of Tech Window